Companies · Other Health Care

HomeThrive, Inc.

NORTHBROOK · Other Health Care

Diligence memoA one-page analyst read on HomeThrive, Inc. — recommendation, valuation, rhythm, risks.
$35.3M
Total raised · real
2
Rounds
0.6×
Latest step-up
Top 11%
Sector rank · raised
Series B
Latest stage · inferred · Mon Jul 22 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

HomeThrive, Inc. looks fair against its niche peers and is quiet on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the health care sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Fair
  • Modeled value is 0.87× the median modeled value of Series B Other Health Care companies in 2022–2024 (91 peers) — value vs value, same stage and era.
  • Within the normal band (87% of peer median) for its niche.
Quiet
  • Last raise 23 mo ago; this sector typically re-raises about every 14 months.
  • Slightly overdue versus sector cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Other Health Care

HomeThrive, Inc. is one of 5377 Other Health Care companies tracked from NORTHBROOK. By capital raised it ranks among the largest (ahead of 90% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
14
Investors (latest)
2024-07-22
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2020-10-05 Raised $15M (real) Modeled valuation $271M (est)Series A2020Series B · 2022-03-21 Raised $17M (real) Modeled valuation $216M (est)Series B2022Series A · 2024-07-22 Raised $13M (real) Modeled valuation $62M (est)Series A2024Series B · 2024-07-22 Raised $21M (real) Modeled valuation $132M (est)Series B2024Series A · 2024-07-22 Raised $12M (real) Modeled valuation $58M (est)Series A2024Series B · 2024-07-22 Raised $18M (real) Modeled valuation $118M (est)Series B2024Series A · 2024-07-22 Raised $10M (real) Modeled valuation $48M (est)Series A2024+$17M+$13M+$21M+$12M+$18M+$10MCumulative $106M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$14.8M · 2020
Series B$16.5M · 2022
Bridge · Series B-stage$13.2M · 2024smaller follow-on
Series B extension$20.5M · 2024
Bridge · Series B-stage$12.2M · 2024smaller follow-on
Series B extension$18.3M · 2024
Bridge · Series B-stage$10.1M · 2024smaller follow-on

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed, Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 50%.

Modeled valuation trajectory
$131.9M
Base estimate est.
$48.2M
Conservative case
$233.6M
Upside case
$114.0M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Ba $15M–$40M round). Valuation is modeled from stage benchmarks scaled by the health care sector profile. Directional, not a quoted figure.

Series A · modeled $271.0M · 2020-10-052020Series B · modeled $216.4M · 2022-03-21Series A · modeled $62.5M · 2024-07-22Series B · modeled $131.9M · 2024-07-22Series A · modeled $57.8M · 2024-07-22Series B · modeled $117.9M · 2024-07-22Series A · modeled $47.8M · 2024-07-222024
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
64%
Survival probability
42% low · 78% high
1.36×/yr
Annual markup
1.64×/yr upside case
1.9 yr
Elapsed time used
1.9 yr actual, capped for stale marks
health care
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
8 mo
Avg between rounds
$9.3M/yr
Capital velocity
5.7 yr
On record since
2020
First round
7
Rounds on file
How it compares to the market

Benchmarked against 5377 companies in Other Health Care. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 15× above median
This company$35.3M
Sector median$2.4M
Latest round — vs other Series B rounds in sector (real $, this stage) 0.6× of median
This company$10.1M
Sector median$17.8M
Modeled value — vs sector median (estimate, all stages) 6.0× above median
This company$131.9M
Sector median$22.1M

Raised more than 90% of sector peers (real $). Modeled value above 83% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series B) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #57 of 91.

This companyCohort peer
$100.0M$1.0B$10.0M$100.0MCapital raised (log)Code Biotherapeutics, Inc. · Series B Raised $47.5M · modeled $465.8M (est)Candesant Biomedical, Inc. · Series B Raised $44.5M · modeled $455.3M (est)Artis Holdings, LLC · Series B Raised $40.0M · modeled $383.5M (est)GIO Blood Ltd · Series B Raised $27.3M · modeled $375.5M (est)Clarapath, Inc. · Series B Raised $40.2M · modeled $348.4M (est)Diality Inc · Series B Raised $42.9M · modeled $337.7M (est)VA Pro 7 SNF Operations Holdings LLC · Series B Raised $32.0M · modeled $333.3M (est)VivoSense, Inc. · Series B Raised $27.0M · modeled $332.6M (est)Tidal Wave GPO, LLC · Series B Raised $34.8M · modeled $324.6M (est)Peachy Corp. · Series B Raised $25.1M · modeled $309.9M (est)Smile Source Holdings, L.P. · Series B Raised $32.2M · modeled $309.0M (est)ASC San Rafael LLC · Series B Raised $28.3M · modeled $295.1M (est)HomeThrive, Inc. (this company) Raised $35.3M · modeled $131.9M (est)HomeThrive, Inc.
CompanyStageRaised · realValue · estvs peer med.
Code Biotherapeutics, Inc.Series B$47.5M$465.8M3.06×
Candesant Biomedical, Inc.Series B$44.5M$455.3M2.99×
Artis Holdings, LLCSeries B$40.0M$383.5M2.52×
GIO Blood LtdSeries B$27.3M$375.5M2.47×
Clarapath, Inc.Series B$40.2M$348.4M2.29×
Diality IncSeries B$42.9M$337.7M2.22×
VA Pro 7 SNF Operations Holdings LLCSeries B$32.0M$333.3M2.19×
VivoSense, Inc.Series B$27.0M$332.6M2.19×
Tidal Wave GPO, LLCSeries B$34.8M$324.6M2.13×
Peachy Corp.Series B$25.1M$309.9M2.04×
Smile Source Holdings, L.P.Series B$32.2M$309.0M2.03×
ASC San Rafael LLCSeries B$28.3M$295.1M1.94×
HomeThrive, Inc. this companySeries B$35.3M$131.9M0.87×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$14.8M2020-10-05$67.0M$271.0M90%
Series B$16.5M2022-03-21$91.7M$216.4M90%
Series A$13.2M2024-07-22$60.2M$62.5M90%
Series B$20.5M2024-07-22$114.0M$131.9M90%
Series A$12.2M2024-07-22$55.7M$57.8M90%
Series B$18.3M2024-07-22$101.9M$117.9M90%
Series A$10.1M2024-07-22$46.1M$47.8M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$14.8M2020-10-05
    • First recorded raise — entered as Series A.
    • 8 investors on this round.
  2. Series B$16.5M2022-03-21
    • Raised 17 mo later, in step with the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 5 investors on this round.
  3. Series A$13.2M2024-07-22
    • Raised again after 28 mo — slower than the ~14 mo sector norm.
    • Round roughly the size of the prior one.
    • 16 investors on this round.
  4. Series B$20.5M2024-07-22
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.5× larger than the prior — scaling up.
    • 19 investors on this round.
  5. Series A$12.2M2024-07-22
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.7× smaller than the prior — bridge or down round.
    • 15 investors on this round.
  6. Series B$18.3M2024-07-22
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.5× larger than the prior — scaling up.
    • 17 investors on this round.
  7. Series A$10.1M2024-07-22
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 1.8× smaller than the prior — bridge or down round.
    • 14 investors on this round.
Intelligence
2025 ~Q1
Modeled next raise · ~8mo cadence
$10.1M
Modeled next size est.range $10.1M$16.2M
0.6×
Last step-up
$9.3M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
David Greenberg12 other2020-10
Glen Tullman11 other2020-10
LEE SHAPIRO9 other2020-10
Robert Garber7 other2020-10
Ittai Harel5 other2024-07
David Jacobs4 other2020-10
Erica Palsis2024-07
Ismat Aziz2024-07
Ittai Harrell2022-03
Ravit Washa Dor2024-07
Tom Archipley2022-03
Registry & provenance

HomeThrive, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1828828
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
7wV-EssCo, Inc.Other Health CareSeries A$6.0M$121.1Mnetwork4 shared operators · same sector
ConsejoSano, Inc.Other Health CareSeries B$18.1M$335.7Mnetwork2 shared operators · same sector · same stage
9Amhealth Inc.Other Health CareSeries B$28.4M$71.1Mnetwork1 shared operator · same sector · same stage
Trainer Rx, Inc.Other Health CareSeries B$47.0M$405.5Mnetwork1 shared operator · same sector · same stage
Eoshealth, Inc.Other Health CareSeries A$8.2M$165.5Mnetwork2 shared operators · same sector
Transcarent, Inc.Other Health CareGrowth/Late$481.0M$5.0Bnetwork2 shared operators · same sector
GHR Acquisition, LLCOther Health CareSeries B$35.3M$123.9Msame sector · same stage
Getlabs, Inc.Other Health CareSeries B$35.7M$161.8Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
ISOThrive Inc.Other Health CareSeries A$24.8M88%
HomeCare Advocacy Network, Inc.Other Health CarePre-Seed$8.9M86%
InHomeTherapy, Inc.Other Health CareSeries A$25.5M86%
Fremont HomePlus, LLCOther Health CarePre-Seed$15.4M85%
HomeBase Treatment, Inc.Other Health CarePre-Seed$3.1M85%
MedArrive Inc.Other Health CareSeries B$76.7M85%
OrthoPreserve, Inc.Other Health CarePre-Seed$327K85%
NVOLVE, Inc.Other Health CarePre-Seed$5.0M85%
Frequently asked
How much funding has HomeThrive, Inc. raised?
HomeThrive, Inc. has raised approximately $35.3M in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is HomeThrive, Inc.'s estimated valuation?
Provath's modeled valuation for HomeThrive, Inc. is approximately $131.9M (modeled range $48.2M–$233.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is HomeThrive, Inc. at?
HomeThrive, Inc.'s latest modeled financing stage is Series B. Its most recent recorded round closed around Mon Jul 22.
What does HomeThrive, Inc. do and where is it based?
HomeThrive, Inc. operates in the Other Health Care sector, based in NORTHBROOK.
Explore related

See where HomeThrive, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at HomeThrive, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.